- License agreement centered around development of a single ADC program
- Usage of Synaffix GlycoConnect®, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagement
Amsterdam, The Netherlands, 9 January 2024 — Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced that it has licensed its ADC technology to Mitsubishi Tanabe Pharma Corporation (“MTPC”), the pharma arm of Mitsubishi Chemical Group (“MCG”).
Synaffix is responsible for the manufacturing of the components that are related to its proprietary technologies, and MTPC is responsible for the research, development, manufacturing and commercialization of the ADC.
Peter van de Sande, Head of Synaffix, said: “This latest licensing deal with MTPC highlights the appeal of our industry-leading ADC technology offering. MTPC is a key collaborator for us, expanding our presence in the APAC region, and we are excited to work alongside such a large and reputable corporation with the aim to make a tangible difference for patients in areas of high unmet medical need.”
